Research ExplorerPublicationsUsing Probability for Pathological Complete Response (pCR) a...

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians

Standard

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians. / Gass, Paul; Untch, Michael; Müller, Volkmar; Möbus, Volker; Thomssen, Christoph; Häberle, Lothar; Erber, Ramona; Hein, Alexander; Jud, Sebastian Michael; Lux, Michael P; Hack, Carolin C; Hartmann, Arndt; Kolberg, Hans-Christian; Ettl, Johannes; Lüftner, Diana; Jackisch, Christian; Beckmann, Matthias W; Janni, Wolfgang; Schneeweiss, Andreas; Fasching, Peter A; Nabieva, Naiba.

In: GEBURTSH FRAUENHEILK, Vol. 78, No. 7, 07.2018, p. 707-714.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gass, P, Untch, M, Müller, V, Möbus, V, Thomssen, C, Häberle, L, Erber, R, Hein, A, Jud, SM, Lux, MP, Hack, CC, Hartmann, A, Kolberg, H-C, Ettl, J, Lüftner, D, Jackisch, C, Beckmann, MW, Janni, W, Schneeweiss, A, Fasching, PA & Nabieva, N 2018, 'Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians', GEBURTSH FRAUENHEILK, vol. 78, no. 7, pp. 707-714. https://doi.org/10.1055/a-0642-9462

APA

Gass, P., Untch, M., Müller, V., Möbus, V., Thomssen, C., Häberle, L., Erber, R., Hein, A., Jud, S. M., Lux, M. P., Hack, C. C., Hartmann, A., Kolberg, H-C., Ettl, J., Lüftner, D., Jackisch, C., Beckmann, M. W., Janni, W., Schneeweiss, A., ... Nabieva, N. (2018). Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians. GEBURTSH FRAUENHEILK, 78(7), 707-714. https://doi.org/10.1055/a-0642-9462

Vancouver

Gass P, Untch M, Müller V, Möbus V, Thomssen C, Häberle L et al. Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians. GEBURTSH FRAUENHEILK. 2018 Jul;78(7):707-714. https://doi.org/10.1055/a-0642-9462

Bibtex

@article{3156d9164c164d9dad9fbc67d9e536c1,
title = "Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians",
abstract = "Background: In women with early breast cancer, a pathological complete response (pCR) after neoadjuvant chemotherapy is reported to be associated with an improvement of the survival. The aim of this survey among physicians was to investigate whether the probability of achieving pCR in patients with a hormone receptor-positive, HER2-negative disease encourages physicians to recommend neoadjuvant chemotherapy.Methods: The study was conducted via an online survey that was sent to 493 physicians, who were either known as members of national guideline committees, heads of breast cancer centers, being high recruiters in clinical trials or leading a private practice. Participants were asked about a specific case that should resemble patients for whom it is unclear, whether they should be treated with chemotherapy.Results: 113 (24.5%) physicians participated at the survey, out of which 96.5% had a work experience of more than 10 years and 94.7% were board certified in their specialty. A total of 84.1% would consider pCR for a decision concerning neoadjuvant chemotherapy. With regard to the pCR probability, 2.7 and 10.6% of the participants demanded at least a pCR rate of 5 and 10%, respectively, while 25.7% were satisfied with 20% probability, and another 25.7% with a pCR rate of 30%.Conclusions: The vast majority of the long-term experienced physicians would embrace the implementation of a further method such as the prediction of pCR probability in clinical routine to support decision making regarding the necessity of neoadjuvant chemotherapy. The cut-off of around 30% pCR probability seems to be a realizable rate to distinguish patient groups.",
keywords = "Journal Article",
author = "Paul Gass and Michael Untch and Volkmar M{\"u}ller and Volker M{\"o}bus and Christoph Thomssen and Lothar H{\"a}berle and Ramona Erber and Alexander Hein and Jud, {Sebastian Michael} and Lux, {Michael P} and Hack, {Carolin C} and Arndt Hartmann and Hans-Christian Kolberg and Johannes Ettl and Diana L{\"u}ftner and Christian Jackisch and Beckmann, {Matthias W} and Wolfgang Janni and Andreas Schneeweiss and Fasching, {Peter A} and Naiba Nabieva",
year = "2018",
month = jul,
doi = "10.1055/a-0642-9462",
language = "English",
volume = "78",
pages = "707--714",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "7",

}

RIS

TY - JOUR

T1 - Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians

AU - Gass, Paul

AU - Untch, Michael

AU - Müller, Volkmar

AU - Möbus, Volker

AU - Thomssen, Christoph

AU - Häberle, Lothar

AU - Erber, Ramona

AU - Hein, Alexander

AU - Jud, Sebastian Michael

AU - Lux, Michael P

AU - Hack, Carolin C

AU - Hartmann, Arndt

AU - Kolberg, Hans-Christian

AU - Ettl, Johannes

AU - Lüftner, Diana

AU - Jackisch, Christian

AU - Beckmann, Matthias W

AU - Janni, Wolfgang

AU - Schneeweiss, Andreas

AU - Fasching, Peter A

AU - Nabieva, Naiba

PY - 2018/7

Y1 - 2018/7

N2 - Background: In women with early breast cancer, a pathological complete response (pCR) after neoadjuvant chemotherapy is reported to be associated with an improvement of the survival. The aim of this survey among physicians was to investigate whether the probability of achieving pCR in patients with a hormone receptor-positive, HER2-negative disease encourages physicians to recommend neoadjuvant chemotherapy.Methods: The study was conducted via an online survey that was sent to 493 physicians, who were either known as members of national guideline committees, heads of breast cancer centers, being high recruiters in clinical trials or leading a private practice. Participants were asked about a specific case that should resemble patients for whom it is unclear, whether they should be treated with chemotherapy.Results: 113 (24.5%) physicians participated at the survey, out of which 96.5% had a work experience of more than 10 years and 94.7% were board certified in their specialty. A total of 84.1% would consider pCR for a decision concerning neoadjuvant chemotherapy. With regard to the pCR probability, 2.7 and 10.6% of the participants demanded at least a pCR rate of 5 and 10%, respectively, while 25.7% were satisfied with 20% probability, and another 25.7% with a pCR rate of 30%.Conclusions: The vast majority of the long-term experienced physicians would embrace the implementation of a further method such as the prediction of pCR probability in clinical routine to support decision making regarding the necessity of neoadjuvant chemotherapy. The cut-off of around 30% pCR probability seems to be a realizable rate to distinguish patient groups.

AB - Background: In women with early breast cancer, a pathological complete response (pCR) after neoadjuvant chemotherapy is reported to be associated with an improvement of the survival. The aim of this survey among physicians was to investigate whether the probability of achieving pCR in patients with a hormone receptor-positive, HER2-negative disease encourages physicians to recommend neoadjuvant chemotherapy.Methods: The study was conducted via an online survey that was sent to 493 physicians, who were either known as members of national guideline committees, heads of breast cancer centers, being high recruiters in clinical trials or leading a private practice. Participants were asked about a specific case that should resemble patients for whom it is unclear, whether they should be treated with chemotherapy.Results: 113 (24.5%) physicians participated at the survey, out of which 96.5% had a work experience of more than 10 years and 94.7% were board certified in their specialty. A total of 84.1% would consider pCR for a decision concerning neoadjuvant chemotherapy. With regard to the pCR probability, 2.7 and 10.6% of the participants demanded at least a pCR rate of 5 and 10%, respectively, while 25.7% were satisfied with 20% probability, and another 25.7% with a pCR rate of 30%.Conclusions: The vast majority of the long-term experienced physicians would embrace the implementation of a further method such as the prediction of pCR probability in clinical routine to support decision making regarding the necessity of neoadjuvant chemotherapy. The cut-off of around 30% pCR probability seems to be a realizable rate to distinguish patient groups.

KW - Journal Article

U2 - 10.1055/a-0642-9462

DO - 10.1055/a-0642-9462

M3 - SCORING: Journal article

C2 - 30057427

VL - 78

SP - 707

EP - 714

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 7

ER -